Clinical Study of ATTR-CM

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jun 21, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating a condition called Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), which affects the heart. The study aims to learn more about how to diagnose and treat this condition, as well as to follow patients over a long period to see how they respond to treatment. The trial is currently looking for participants, including both patients with ATTR-CM and individuals who carry the gene for this condition.

To be eligible for the study, participants need to be between 18 and 90 years old and able to understand the study and cooperate with the medical team. It's important that they can provide informed consent, meaning they understand what participation involves. Those who join the trial will have the opportunity to contribute to important research that may help improve care for others with ATTR-CM in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients and gene carriers of ATTR-CM confirmed in the Second Affiliated Hospital of Zhejiang University School of Medicine, regardless of gender, age 18-90 years old;
• • Patients who have the ability to understand the test and can cooperate with investigators
• Exclusion Criteria:
• • Patients who unable to understand or unwilling to fill in informed consent forms or follow visitors